期刊文献+

肝硬化患者门静脉血栓形成的相关危险因素 被引量:22

Risk factors of portal vein thrombosis in patients with liver cirrhosis
下载PDF
导出
摘要 目的:研究肝硬化患者门静脉血栓(portal vein thrombosis,PVT)形成的相关危险因素.方法:2006-2007年我院确诊的肝炎和酒精性肝硬化患者90例,其中23例肝硬化PVT患者作为血栓组,67例肝硬化非血栓患者作为对照组.采用凝固法检测凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)和纤维蛋白原(Fib),发色底物法检测抗凝血酶-Ⅲ(AT-Ⅲ),酶联免疫吸附双抗体夹心法检测蛋白-C(PC)、蛋白-S(PS)、D-二聚体(d-dimer)、组织纤溶酶原激活物剂(t-PA)和组织纤溶酶原激活物抑制剂-1(PAI-1).将门静脉血栓形成的相关因素纳入研究,进行统计学分析.结果:d-dimer升高是肝硬化PVT形成的危险因素(OR=13.236,95%CI:2.345-74.721),PC和AT-Ⅲ升高是肝硬化PVT形成的保护因素(OR=0.242,95%CI:0.08-0.727;OR=0.917,95%CI:0.841-0.999).研究未能提示性别、肝功能Child-Pugh分级和APTT等止凝血指标是PVT形成的危险因素.结论:d-dimer升高是肝硬化PVT形成的危险因素,PC和AT-Ⅲ升高是肝硬化PVT形成的保护因素. AIM: To determine risk factors of portal vein thrombosis (PVT) in liver cirrhosis patients. METHODS: Ninety patients diagnosed as hep-atitis or non-alcoholic liver cirrhosis from 2006 to 2007 in our hospital were reviewed, includ-ing 23 liver cirrhosis cases with PVT in throm-bosis group and 67 without PVT in the control group. A coagulation method was used to mea-sure prothrombin time (PT), activated partial prothrombin time (APTT) and fibrinogen (Fib); hair color substrate was used to detect anti-thrombin-Ⅲ (AT-Ⅲ); ELISA was used to detect protein C (PC), protein S (PS), d-dimer, t-PA and PAI-1. Using an analyzer and following manufacturer instructions, a series of hemostat-ic indexes were performed on 90 LC patients with and without PVT. SPSS software was used for statistic analysis. RESULTS: Logistic regression model showed that the increased d-dimer was a risk factor (OR= 13.236, 95% CI: 2.345-74.721) and the increased PC and AT-Ⅲ were the protective factors in PVT development (OR = 0.242, 95% CI: 0.08-0.727; OR = 0.917, 95% CI: 0.841-0.999). No differences were found in gender, Child-Pugh scores and APTT et al. CONCLUSION: The increased d-dimer was the risk factor for liver cirrhosis patients with PVT while PC and AT-Ⅲ were the protective factors.
作者 张冬磊 杨宁
出处 《世界华人消化杂志》 CAS 北大核心 2008年第27期3106-3109,共4页 World Chinese Journal of Digestology
关键词 肝硬化 门静脉血栓 D-二聚体 危险因素 Liver cirrhosis Portal vein thrombosis D-dimer Risk factor
  • 相关文献

参考文献9

  • 1中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14009
  • 2Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..酒精性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):164-166. 被引量:271
  • 3Okuda K, Ohnishi K, Kimura K, Matsutani S, Sumida M, Goto N, Musha H, Takashi M, Suzuki N, Shinagawa T. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology 1985; 89:279-286.
  • 4Mangia A, Villani MR, Cappucci G, Santoro R, Ricciardi R, Facciorusso D, Leandro G, Caruso N, Andriulli A. Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. Eur J Gastroenterol Hepatol 2005; 17:745-751.
  • 5Romero Gomez M, Suarez Garcia E, Lopez Lacomba D, Marchante I, Grande L, Castro Fernandez M. Antiphospholipid antibodies are related to portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2000; 31:237-240.
  • 6Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, D'Andrea G, Marmo R, Ames PR, Balzano A. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000; 31:345-348.
  • 7Erkan O, Bozdayi AM, Disibeyaz S, Oguz D, Ozcan M, Bahar K, Karayalcin S, Ozden A, Bozkaya H, Yurdaydin C, Uzunalimoglu O. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. Eur J Gastroenterol Hepatol 2005; 17: 339-343.
  • 8Violi F, Ferro D, Basili S, Quintarelli C, Musca A, Cordova C, Balsano F. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis. Hepatology 1993; 17:78-83.
  • 9Romero-Gomez M, Gutierrez-Tous R, Delgado-Mije D. Anticoagulation therapy for recent portal vein thrombosis in a patient with liver cirrhosis suffering from variceal rebleeding. Gastroenterology 2002; 122: 2095.

二级参考文献15

  • 1胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 2Lok AS,McMahon B J; Practice Guidelines Committee,American Association for the Study of Liver Diseases (AASLD).Chronic hepatitis B:update of recommendations.Hepatology,2004,39:857-861.
  • 3Sanyal AJ.American Gastroenterological Association technical review on nonalcoholic fatty liver disease.Gastroenterology,2002,123:1705-1725.
  • 4Graif M,Yanuka M,Baraz M,et al.Quantitative estimation of attenuation in ultrasound video images:correlation with histology in diffuse liver disease.Invest Radiol,2000,35:319-324.
  • 5Ataseven H,Yildrim MH,Yalniz M,et al.Correlation between computerized tomographic findings and histopathologic grade/stage in non-alcoholic steatohepatitis.J Hepatol,2003,38(Suppl 2):A4177.
  • 6Farrell GC,George J,Pauline de la M.Hall,et al,eds.Fatty liver diseas:NASH and related disorders.Oxford:Blackwell Publishing,2005.159-207.
  • 7McCullough AJ,O'Connor JF.Alcoholic liver disease:proposed recommendations for the American College of Gastroenterology.Am J Gastroenterol,1998,93:2022-2036.
  • 8Stickel F,Hoehn B,Schuppan D,et al.Review article:Nutritional therapy in alcoholic liver disease.Aliment Pharmacol Ther,2003,18:357-373.
  • 9Mathurin P,Mendenhall CL,Carithers RLJr,et al.Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH):individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH.J Hepatol,2002,36:480-487.
  • 10Imperiale TF,O'Connor JB,McCullough AJ.Corticosteroids are effective in patients with severe alcoholic hepatitis.Am J Gastroenterol,1999,94:3066-3068.

共引文献14248

同被引文献179

引证文献22

二级引证文献140

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部